Identification of Blood Biomarkers in Glioblastoma by SWATH Mass Spectrometry and Quantitative Targeted Absolute Proteomics

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Mar 8

PMID 29513714

Citations 52

Authors

Eisuke Miyauchi

Takuya Furuta

Sumio Ohtsuki

Masanori Tachikawa

Yasuo Uchida

Hemragul Sabit

Wataru Obuchi

Tomoko Baba

Michitoshi Watanabe

Tetsuya Terasaki

Mitsutoshi Nakada

Affiliations

Soon will be listed here.

Abstract

Molecular biomarkers in blood are needed to aid the early diagnosis and clinical assessment of glioblastoma (GBM). Here, in order to identify biomarker candidates in plasma of GBM patients, we performed quantitative comparisons of the plasma proteomes of GBM patients (n = 14) and healthy controls (n = 15) using SWATH mass spectrometry analysis. The results were validated by means of quantitative targeted absolute proteomics analysis. As a result, we identified eight biomarker candidates for GBM (leucine-rich alpha-2-glycoprotein (LRG1), complement component C9 (C9), C-reactive protein (CRP), alpha-1-antichymotrypsin (SERPINA3), apolipoprotein B-100 (APOB), gelsolin (GSN), Ig alpha-1 chain C region (IGHA1), and apolipoprotein A-IV (APOA4)). Among them, LRG1, C9, CRP, GSN, IGHA1, and APOA4 gave values of the area under the receiver operating characteristics curve of greater than 0.80. To investigate the relationships between the biomarker candidates and GBM biology, we examined correlations between plasma concentrations of biomarker candidates and clinical presentation (tumor size, progression-free survival time, or overall survival time) in GBM patients. The plasma concentrations of LRG1, CRP, and C9 showed significant positive correlations with tumor size (R2 = 0.534, 0.495, and 0.452, respectively).

Citing Articles

Cross-Sectional and Longitudinal Associations of Serum LRG1 with Severity and Prognosis Among Adult Community-Acquired Pneumonia Patients.

Wang Y, Jiang Y, Xie M, Qi B, Pu K, Du W J Inflamm Res. 2024; 17:7951-7962.

PMID: 39502939 PMC: 11537034. DOI: 10.2147/JIR.S485932.

Proteomics Studies on Extracellular Vesicles Derived from Glioblastoma: Where Do We Stand?.

Giuliani P, De Simone C, Febo G, Bellasame A, Tupone N, Di Virglio V Int J Mol Sci. 2024; 25(18).

PMID: 39337267 PMC: 11431518. DOI: 10.3390/ijms25189778.

Machine learning-based analysis identifies and validates serum exosomal proteomic signatures for the diagnosis of colorectal cancer.

Yin H, Xie J, Xing S, Lu X, Yu Y, Ren Y Cell Rep Med. 2024; 5(8):101689.

PMID: 39168094 PMC: 11384723. DOI: 10.1016/j.xcrm.2024.101689.

A Synopsis of Biomarkers in Glioblastoma: Past and Present.

Tataranu L, Turliuc S, Rizea R, Dricu A, Alexandru O, Staicu G Curr Issues Mol Biol. 2024; 46(7):6903-6939.

PMID: 39057054 PMC: 11275428. DOI: 10.3390/cimb46070412.

Proteomics of tumor and serum samples from isocitrate dehydrogenase-wildtype glioblastoma patients: is the detoxification of reactive oxygen species associated with shorter survival?.

Clavreul A, Guette C, Lasla H, Rousseau A, Blanchet O, Henry C Mol Oncol. 2024; 18(11):2783-2800.

PMID: 38803161 PMC: 11547244. DOI: 10.1002/1878-0261.13668.

References

Guergova-Kuras M, Kurucz I, Hempel W, Tardieu N, Kadas J, Malderez-Bloes C . Discovery of lung cancer biomarkers by profiling the plasma proteome with monoclonal antibody libraries. Mol Cell Proteomics. 2011; 10(12):M111.010298. PMC: 3237079. DOI: 10.1074/mcp.M111.010298. View

Gautam P, Nair S, Gupta M, Sharma R, Polisetty R, Uppin M . Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis. PLoS One. 2012; 7(9):e46153. PMC: 3461020. DOI: 10.1371/journal.pone.0046153. View

Hormigo A, Gu B, Karimi S, Riedel E, Panageas K, Edgar M . YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res. 2006; 12(19):5698-704. DOI: 10.1158/1078-0432.CCR-06-0181. View

Jayaram S, Gupta M, Polisetty R, Cho W, Sirdeshmukh R . Towards developing biomarkers for glioblastoma multiforme: a proteomics view. Expert Rev Proteomics. 2014; 11(5):621-39. DOI: 10.1586/14789450.2014.939634. View

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

Baumann H, Onorato V, Gauldie J, Jahreis G . Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors and monokines in rat hepatoma cells. J Biol Chem. 1987; 262(20):9756-68. View

Kros J, Mustafa D, Dekker L, Sillevis Smitt P, Luider T, Zheng P . Circulating glioma biomarkers. Neuro Oncol. 2014; 17(3):343-60. PMC: 4483097. DOI: 10.1093/neuonc/nou207. View

Furukawa K, Kawamoto K, Eguchi H, Tanemura M, Tanida T, Tomimaru Y . Clinicopathological Significance of Leucine-Rich α2-Glycoprotein-1 in Sera of Patients With Pancreatic Cancer. Pancreas. 2014; 44(1):93-8. DOI: 10.1097/MPA.0000000000000205. View

Polanski M, Anderson N . A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights. 2009; 1:1-48. PMC: 2716785. View

10.

Ilzecka J, Ilzecki M . APRIL is increased in serum of patients with brain glioblastoma multiforme. Eur Cytokine Netw. 2007; 17(4):276-80. View

11.

Rauniyar N, Peng G, Lam T, Zhao H, Mor G, Williams K . Data-Independent Acquisition and Parallel Reaction Monitoring Mass Spectrometry Identification of Serum Biomarkers for Ovarian Cancer. Biomark Insights. 2017; 12:1177271917710948. PMC: 5462478. DOI: 10.1177/1177271917710948. View

12.

Lee J, Cho B, Bae M, Lee C, Park I, Kim D . Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. Lung Cancer. 2008; 63(1):106-10. DOI: 10.1016/j.lungcan.2008.04.011. View

13.

Zhou J, Cheng Y, Tang L, Martinka M, Kalia S . Up-regulation of SERPINA3 correlates with high mortality of melanoma patients and increased migration and invasion of cancer cells. Oncotarget. 2016; 8(12):18712-18725. PMC: 5386641. DOI: 10.18632/oncotarget.9409. View

14.

Wang H, Cheng B, Chen Q, Wu S, Lv C, Xie G . Time course of plasma gelsolin concentrations during severe sepsis in critically ill surgical patients. Crit Care. 2008; 12(4):R106. PMC: 2575595. DOI: 10.1186/cc6988. View

15.

Popescu I, Codrici E, Albulescu L, Mihai S, Enciu A, Albulescu R . Potential serum biomarkers for glioblastoma diagnostic assessed by proteomic approaches. Proteome Sci. 2014; 12(1):47. PMC: 4189552. DOI: 10.1186/s12953-014-0047-0. View

16.

Chong P, Lee H, Loh M, Choong L, Lin Q, So J . Upregulation of plasma C9 protein in gastric cancer patients. Proteomics. 2010; 10(18):3210-21. PMC: 3760195. DOI: 10.1002/pmic.201000127. View

17.

Yang J, Tan D, Asch H, Swede H, Bepler G, Geradts J . Prognostic significance of gelsolin expression level and variability in non-small cell lung cancer. Lung Cancer. 2004; 46(1):29-42. DOI: 10.1016/j.lungcan.2004.03.022. View

18.

Wu J, Yin H, Zhu J, Buckanovich R, Thorpe J, Dai J . Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study. PLoS One. 2015; 10(3):e0121112. PMC: 4370724. DOI: 10.1371/journal.pone.0121112. View

19.

Iwamoto F, Hottinger A, Karimi S, Riedel E, Dantis J, Jahdi M . Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol. 2011; 13(11):1244-51. PMC: 3199155. DOI: 10.1093/neuonc/nor117. View

20.

Petrik V, Saadoun S, Loosemore A, Hobbs J, Opstad K, Sheldon J . Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem. 2008; 54(4):713-22. DOI: 10.1373/clinchem.2007.096792. View